Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Phone App Breathing Exercises Help Respiratory Muscle Strength

Breathing exercises via a mobile app help improve respiratory muscle strength and mobility in the diaphragm in patients with severe chronic obstructive pulmonary disease (COPD), a study says. The study, “Respiratory muscle training program supplemented by a cell-phone application in COPD patients with severe airflow limitation,” was published…

Partnership Seeks to Lower Costs of COPD Meds

GoodRx, a platform for healthcare savings in the U.S., and pharmaceutical company Boehringer Ingelheim have teamed up to help lower out-of-pocket medication costs  for people with chronic obstructive pulmonary disease (COPD) or type 2 diabetes. Patients will be able to enroll in sponsored copay programs to access  Boehringer…

Mepolizumab Lessens Exacerbations, Improves Quality of Life

Treatment with mepolizumab, an antibody designed to lower the levels of eosinophils — immune cells linked with worse chronic obstructive pulmonary disease (COPD) — was found to reduce the annual rate of exacerbations and improve health-related quality of life in people with eosinophil-associated COPD. The findings, from a meta-analysis…

COPD Foundation, DevPro Biopharma Partner to Boost New Therapy Development

The Chronic Obstructive Pulmonary Disease Foundation and DevPro Biopharma have established a partnership to develop new therapies for people with chronic obstructive pulmonary disease (COPD) and other lung disorders. The collaborators will work to identify potential therapies and speed their development and possible regulatory approval. The aim is to enable new treatments…